Lazard Asset Management
KNSA icon

Lazard Asset Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Lazard Asset Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.3M Buy
67,291
+45,859
+214% +$2.38M 0.01% 670
2026
Q1 		$1.03M Sell
21,432
-118,869
-85% -$5.27M ﹤0.01% 1149
2025
Q4 		$5.79M Buy
140,301
+1,989
+1% +$79.8K 0.01% 516
2025
Q3 		$5.37M Buy
138,312
+123,131
+811% +$4M 0.01% 563
2025
Q2 		$420K Buy
15,181
+12,310
+429% +$313K ﹤0.01% 1541
2025
Q1 		$63K Sell
2,871
-227
-7% -$4.67K ﹤0.01% 1943
2024
Q4 		$61K Buy
+3,098
New +$70.7K ﹤0.01% 1931
2024
Q2 		– Sell
-3,607
Closed -$71K – 2341
2024
Q1 		$71K Buy
+3,607
New +$70.4K ﹤0.01% 1640
2023
Q4 		– Sell
-3,502
Closed -$60K – 2363
2023
Q3 		$60K Buy
+3,502
New +$59K ﹤0.01% 1798
2023
Q1 		– Sell
-4,648
Closed -$69K – 2432
2022
Q4 		$69K Buy
+4,648
New +$67.7K ﹤0.01% 1668
2022
Q3 		– Sell
-10,546
Closed -$102K – 2448
2022
Q2 		$102K Buy
10,546
+4,826
+84% +$45K ﹤0.01% 1499
2022
Q1 		$56K Buy
5,720
+1,961
+52% +$20.8K ﹤0.01% 1686
2021
Q4 		$44K Buy
+3,759
New +$46.2K ﹤0.01% 1796

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Lazard Asset Management's KNSA Position: Q2 2026 in Review

Lazard Asset Management increased its Kiniksa Pharmaceuticals (KNSA) stake by 214% in Q2 2026, buying an estimated $2.38M and bringing the position to 67,291 shares worth $4.3M. The position accounts for 0.01% of the portfolio, ranked #670.

Lazard Asset Management first reported a position in KNSA in Q4 2021 and has held it in 13 quarters since. The position peaked at $5.79M in Q4 2025. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Lazard Asset Management held 67,291 shares of Kiniksa Pharmaceuticals worth $4.3M as of Q2 2026.
  • Lazard Asset Management bought 45,859 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $2.38M.
  • Kiniksa Pharmaceuticals made up 0.01% of Lazard Asset Management's portfolio in Q2 2026, its #670 holding.
  • Lazard Asset Management first reported a position in Kiniksa Pharmaceuticals in Q4 2021 and has held it in 13 quarters since.
  • Lazard Asset Management's Kiniksa Pharmaceuticals position peaked at $5.79M in Q4 2025.
  • 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.